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C

oronavirus Disease 2019 (COVID-19) caused 2
million cases and more than 150,000 deaths worldwide as of mid-April 2020.1 Clinical trials are under way to
assess the efﬁcacy of a variety of antiviral drugs; however,
many of these drugs have toxicities and thus far no drug has
been proven to improve outcomes in patients with COVID-19.
Famotidine is a histamine-2 receptor antagonist that
suppresses gastric acid production. In vitro, famotidine inhibits human immunodeﬁciency virus replication.2 Recently,
Wu et al.3 used computational methods to predict structures
of proteins encoded by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) genome and identiﬁed
famotidine as one of the drugs most likely to inhibit the 3chymotrypsin-like protease (3CLpro), which processes proteins essential for viral replication.4 We hypothesized that
famotidine would be associated with improved clinical
outcomes among hospitalized patients with COVID-19. To
explore this, we performed a retrospective cohort study at a
single academic center located at the epicenter of the
COVID-19 pandemic in the United States.

Methods
Complete methods are available in the Supplementary
Materials. In brief, adults were eligible for the study if they
were admitted to our institution from February 25, 2020, to
April 13, 2020, and tested positive for SARS-CoV-2 within no
more than 72 hours following admission. Patients were excluded
if they died or were intubated within 48 hours following hospital
admission. The primary exposure was use of famotidine (any
dose, form of administration, or duration), classiﬁed as present if
famotidine was received within 24 hours of hospital admission
and otherwise as absent. The primary outcome was a composite
of death or endotracheal intubation from hospital day 2 to day 30
(intubation-free survival). This follow-up period avoided

immortal time bias because the exposure was classiﬁed based on
the 24-hour period after hospitalization and the at-risk period
began on hospital day 2. Cox proportional hazards modeling was
performed on the full cohort, and a matched subset was examined with propensity scoring matching to balance baseline
characteristics based on use of famotidine.

Results
Population and Use of Famotidine
A total of 1620 patients met criteria for analysis,
including 84 patients (5.1%) who received famotidine
within 24 hours of hospital admission. Home use of famotidine was documented on admission medication reconciliation in 15% of those who used famotidine while
hospitalized compared with 1% of those who did not
(P < .01). Twenty-eight percent of all famotidine doses were
intravenous; 47% were 20 mg, 35% were 40 mg, and 17%
were 10 mg. Famotidine users received a median 5.8 days of
drug for a total median dose of 136 mg (63–233 mg). There
were minimal differences comparing patients who used
famotidine with those who did not, and balance between the
groups was further improved after propensity score
matching (Supplementary Table 1).

Death or Intubation
A total of 142 (8.8%) patients were intubated and 238
(15%) died; 340 (21%) patients met the composite study
outcome. In crude analysis, use of famotidine was signiﬁcantly associated with reduced risk for the composite
outcome of death or intubation (Figure 1A, log-rank
P < .01). This association was driven primarily by the relationship between famotidine and death (Figure 1B, log-rank
Abbreviations used in this paper: CI, conﬁdence interval; COVID-19,
Coronavirus Disease 2019; PPI, proton pump inhibitor; SARS-CoV-2,
severe acute respiratory syndrome coronavirus 2.
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Figure
1. Kaplan-Meier
plot
showing
(A)
intubation-free
survival
and (B) survival through a
maximum of 30 days after
hospital admission, stratiﬁed by use of famotidine.
Patients were included in
the study if they survived
without intubation for 2
days following hospital
admission. Use of famotidine was classiﬁed as
present if it was received
within the ﬁrst 24 hours
following hospital admission (any dose, form of
administration, or duration)
and otherwise as absent.
The at-risk time began on
hospital day 2 (indicated
with a dashed red line) and
patients were followed
until hospital day 30. This
study design avoided potential for immortal time
bias because the exposure
was classiﬁed before the
start of the at-risk period.

P < .01) and when those who died before intubation were
excluded, there was no association between use of famotidine
and intubation (log-rank P ¼ .40). After adjusting for baseline
patient characteristics, use of famotidine remained independently associated with risk for death or intubation
(Supplementary Table 2, adjusted hazard ratio 0.42, 95%
conﬁdence interval [CI] 0.21–0.85) and this remained

unchanged after propensity score matching to further balance the covariables (hazard ratio 0.43, 95% CI 0.21–0.88).

Additional Analyses
Use of proton pump inhibitors (PPIs) was analyzed because
PPIs are also gastric acid suppression medications with similar
indications as famotidine. There was a no protective effect
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Conclusions
This retrospective study found that, in patients hospitalized with COVID-19, famotidine use was associated with a
reduced risk of clinical deterioration leading to intubation or
death. The study was premised on the assumption that use of
famotidine represented a continuation of home use, but
documentation of why famotidine was given was poor. The
results were speciﬁc for famotidine (no protective association
was seen for PPIs) and also speciﬁc for COVID-19 (no protective association in patients without COVID-19). A lower
peak ferritin value was observed among users of famotidine,
supporting the hypothesis that use of famotidine may
decrease cytokine release in the setting of SARS-CoV-2 infection. A randomized controlled trial is currently under way to
determine whether famotidine can improve clinical outcomes
in hospitalized patients with COVID-19 (NCT04370262).
Famotidine has not previously been studied in patients for
antiviral effects, and there are limited relevant prior data. An
untargeted computer modeling analysis identiﬁed famotidine
as one of the highest-ranked matches for drugs predicted to
bind 3CLpro,3 a SARS-CoV-2 protease that generates nonstructure proteins critical to viral replication.4 In the 1990s,
histamine-2 receptor antagonists including famotidine were
shown to inhibit human immunodeﬁciency virus replication
without affecting lymphocyte viability in vitro.2,5,6
There are limitations to the study. It was observational,
and we cannot exclude the possibility of unmeasured confounders or hidden bias that account for the association
between famotidine use and improved outcomes. No samples were gathered, and mechanism cannot be directly
assessed. Finally, this was a single-center study, which may
limit generalizability of the ﬁndings.
In sum, in patients hospitalized with COVID-19 and not
initially intubated, famotidine use was associated with a 2-fold
reduction in clinical deterioration leading to intubation or
death. These ﬁndings are observational and should not be
interpreted to mean that famotidine has a protective effect
against COVID-19. Randomized controlled trials are under way.

www.gastrojournal.org, and at https://doi.org/10.1053/
j.gastro.2020.05.053.
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associated with use of PPIs (adjusted hazard ratio 1.34, 95% CI
1.06–1.69). Next, 784 patients without COVID-19 who were
hospitalized during the same study period were analyzed;
among these patients, famotidine was not associated with
reduced risk for death or intubation (24 deaths or intubations,
log-rank P ¼ .70). The maximum plasma ferritin value during
the hospitalization was assessed to address the hypothesis that,
by blocking viral replication, famotidine reduces cytokine storm
during COVID-19. Median ferritin was 708 ng/mL (interquartile
range 370–1152) among users of famotidine vs 846 ng/mL
(interquartile range 406–1552) among nonusers (rank-sum
P ¼ .03).
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Supplementary Methods
Population
Adults aged 18 years or older were eligible for the study if
they were admitted to Columbia University Irving Medical
Center or its afﬁliate the Allen Pavilion from February 25, 2020,
to April 13, 2020, and tested positive for SARS-CoV-2 by nasopharyngeal polymerase chain reaction at presentation or within
no more than 72 hours following admission. This 72-hour
window was selected because, during the earliest phase of the
SARS-CoV-2 pandemic, testing availability was limited and
could take up to 72 hours for a result. Patients were excluded if
they survived less than 48 hours following hospital admission
or if they required urgent or semi-urgent intubation within 48
hours of hospital admission. This study was approved by the
institutional review board of the Columbia University Irving
Medical Center.

Exposure
The primary exposure was use of famotidine, classiﬁed as
present if famotidine was received within 24 hours of hospital
admission and otherwise classiﬁed as absent. Famotidine use
was ascertained directly from electronic medical order entry
records and could be intravenous or oral, at any dose or duration. Home use of famotidine was examined to understand the
reason underlying in-hospital use of famotidine and was classiﬁed based on electronic medication reconciliation performed
at the time of hospital admission.

Primary Outcome
The primary outcome was a composite of death or
endotracheal intubation within 30 days of hospital admission (intubation-free survival). Mortality data were ascertained from the electronic medical record (EMR), which
interfaces with the social security death index. Endotracheal
intubation was ascertained from EMR documentation of
need for mechanical ventilation. The rationale for the combined primary outcome was 2-fold: (1) many patients who
deteriorated clinically died without being intubated, often
due to transition to palliative care; (2) hospitalization stays
for intubated patients with COVID-19 have been very long,
and many intubated patients with COVID-19 at the time of
the analyses may ultimately not survive.

Covariables
Based on emerging reports of risk factors for COVID-19,
the following covariables were selected for inclusion in the
analysis: preexisting diabetes, hypertension, coronary artery
disease, heart failure, end-stage renal disease or chronic
kidney disease, and chronic pulmonary disorders, all classiﬁed based on the presence of corresponding International
Classiﬁcation of Diseases, 10th Revision codes at the time of
hospital admission; obesity, classiﬁed based on body mass
index; and age, classiﬁed as <50 years, 50 to 65 years, and
>65 years. To assess severity of COVID-19, the ﬁrst recorded form of supplemental oxygen after triage was captured
and was classiﬁed as room air, nasal cannula oxygen, or
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non-rebreather/similar. Use of PPIs was classiﬁed in the
same manner as use of famotidine so that PPIs could be
evaluated to test whether any effects of famotidine might be
related to acid suppression. The maximum value of plasma
ferritin was obtained during the study period for each patient to use as a surrogate for the extent of cytokine storm
(normal laboratory range 13.0 to 150.0 ng/mL).

Statistical Approach
Categorical variables were compared across exposure
groups using c2 tests. Full and reduced Cox proportional
hazards models were constructed within the complete
cohort, with patients followed from the time of hospital
admission until the ﬁrst of the following events: death,
intubation, 30 days of follow-up, or the close of the study on
April 20, 2020. Because patients were excluded if they died
or were intubated before hospital day 2, this effectively
meant that patients were followed from day 2 to day 30.
This design was selected to avoid immortal time bias (ie,
because the exposure was classiﬁed based on the 24-hour
period after hospitalization and the at-risk period did not
begin until hospital day 2). Cox proportional hazards
modeling was performed on the full cohort, and a matched
subset was examined with propensity scoring matching to
balance baseline characteristics based on use of famotidine.
This provided the opportunity for a minimum of 7 days of
follow-up time for all patients in the study. The proportional
hazards assumption was veriﬁed by visual inspection of time-toevent data and by testing for a nonzero slope in the Schoenfeld
residuals (11). The full Cox model included all baseline variables.
For the reduced model, variables were dropped stepwise unless
they had a signiﬁcant independent relationship with the composite
outcome or unless they altered the b-coefﬁcient representing
famotidine by at least 10%. Propensity score matching was then
performed to balance the baseline characteristics of patients with
respect to use of famotidine with a 5:1 nearest-neighbor matching
strategy and a caliper of 0.2. The primary analysis was conducted
as a time-to-event model within the propensity score–matched
cohort, using the same approach. All analyses were performed
using STATA statistical software (version 14; StataCorp, College
Station, TX) at the a ¼ 0.05 level of signiﬁcance.

Additional Analyses
Several sensitivity analyses were performed. First, use of
PPIs was compared with no PPIs within the complete (unmatched) cohort after excluding those who used famotidine.
The purpose of this analysis was to test whether unmeasured patient characteristics related to use of acid suppression rather than famotidine were associated with
improved outcomes in COVID-19. Second, an additional
study cohort was built including records from patients who
tested negative for SARS-CoV-2 during the study period.
Within this cohort, use of famotidine was compared with no
famotidine to test whether unmeasured patient characteristics related to use of famotidine were associated with
improved outcomes regardless of reason for hospitalization
(ie, to test whether the observed association with famotidine was speciﬁc for patients with COVID-19).
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Supplemental Table 1.Patient Characteristics at the Time of Hospital Admission for COVID-19, Stratiﬁed by Use of
Famotidine
Complete cohort

Characteristics
Age (y)
<50
50–65
>65
Female sex
Race/ethnicity
Hispanic
White, non-hispanic
Black, non-hispanic
Other
BMI, kg/m2
<25.0
25.0–29.9 (overweight)
30 (obese)
Not recorded
Comorbidities
Diabetes
Hypertension
CAD
Heart failure
ESRD or CKD
Chronic pulmonary disorders
Initial oxygen requirement
Room air
Nasal canula
Non-rebreather or similar

Famotidine
(n ¼ 84),
n (%)

No famotidine
(n ¼ 1536),
n (%)

After propensity score matching

P value

Famotidine
(n ¼ 84),
n (%)

No famotidine
(n ¼ 420),
n (%)

P value

.39
13
31
40
39

(15)
(37)
(48)
(46)

320
483
733
864

(21)
(31)
(48)
(56)

25
19
18
22

(30)
(23)
(21)
(26)

601
336
322
277

(39)
(22)
(21)
(18)

15
30
22
17

(18)
(36)
(26)
(20)

295
388
434
419

(19)
(25)
(28)
(27)

24
29
9
7
11
2

(29)
(35)
(11)
(8)
(13)
(2)

311
428
109
85
130
120

(20)
(28)
(7)
(6)
(8)
(8)

.63
.20

.51
13
31
40
39

(15)
(37)
(48)
(46)

57
184
179
208

(14)
(44)
(43)
(50)

25
19
18
22

(30)
(23)
(21)
(26)

127
82
102
109

(30)
(20)
(24)
(26)

15
30
22
17

(18)
(36)
(26)
(20)

66
157
110
87

(16)
(37)
(26)
(21)

24
29
9
7
11
2

(29)
(35)
(11)
(8)
(13)
(2)

106
124
37
26
47
6

(25)
(30)
(9)
(6)
(11)
(11)

.17

25 (30)
38 (45)
21 (25)

378 (25)
678 (44)
480 (31)

.07
.19
.21
.28
.14
.07
.39

.60
.90

.97

25 (30)
38 (45)
21 (25)

116 (28)
187 (44)
117 (28)

BMI, body mass index; CAD, coronary artery disease; CKD, chronic kidney disease; ESRD, end-stage renal disease.

.52
.36
.58
.47
.62
.52
.85
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Supplemental Table 2.Final Cox Proportional Hazards Model of risk factors for death or Intubation Among Patients With
COVID-19
Hazard ratio (95% CI)
Characteristics
Famotidine
No
Yes
Age (y)
<50
50–65
>65
Sex
Male
Female
Race/ethnicity
Hispanic
White, non-Hispanic
Black, non-Hispanic
Other
Body mass index, kg/m2
<25.0
25.0–29.9 (overweight)
30 (obese)
Not recorded
Comorbidities
Diabetes
Hypertension
CAD
Heart failure
ESRD or CKD
Chronic pulmonary disorders
Initial oxygen requirement
Room air
Nasal canula
Non-rebreather

Death or intubation/n
at risk (%)

Full model

Final model

332/1536 (22)
8/84 (10)

Reference
0.43 (0.21–0.86)

Reference
0.42 (0.21–0.85)

19/333 (5.7)
75/514 (15)
246/773 (32)

Reference
2.94 (1.77–4.89)
7.51 (4.66–12.1)

Reference
3.03 (1.83–5.03)
7.68 (4.79–12.3)

197/909 (22)
143/711 (20)

Reference
1.11 (0.89–1.38)

—

129/626 (21)
84/355 (24)
59/340 (17)
68/299 (23)

Reference
0.99 (0.75–1.31)
0.82 (0.60–1.13)
1.14 (0.85–1.53)

—

86/310
92/418
89/456
73/436

Reference
0.88 (0.65–1.18)
0.97 (0.72–1.31)
0.67 (0.49–0.92)

—

(28)
(22)
(20)
(17)

72/335 (21)
94/457 (21)
24/118 (20)
24/92 (26)
33/141 (23)
29/122 (24)

1.02
0.72
0.77
1.06
1.16
1.29

(0.75–1.37)
(0.54–0.97)
(0.49–1.21)
(0.67–1.67)
(0.77–1.75)
(0.87–1.93)

—
0.74 (0.58–0.94)
—
—
—
—

52/403 (13)
155/716 (22)
133/501 (27)

Reference
1.60 (1.17–2.19)
2.48 (1.79–3.44)

—
1.63 (1.19–2.24)
2.39 (1.73–3.29)

CAD, coronary artery disease; CKD, chronic kidney disease; ESRD, end-stage renal disease.

